Form 4: Disc Medicine COO Trades Shares Under 10b5-1 Plan

Disc Medicine, Inc. (IRON) reports that Chief Operating Officer Jonathan Yen-Wen Yu executed a Rule 10b5-1 trading plan, involving the acquisition and disposition of company stock.

Summary

• Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine, Inc., engaged in stock transactions on June 26, 2026.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on March 17, 2026.
• The plan involved the acquisition of 300 shares of common stock at $13.50 per share.
• The plan also involved the disposition of 300 shares of common stock at $72.50 per share.
• Following these transactions, Mr. Yu beneficially owns 54,624 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves insider transactions, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading.

Positives

• The transactions were executed under a Rule 10b5-1 plan, which is designed to prevent insider trading concerns by establishing a pre-determined trading strategy.
• The acquisition of shares at a lower price ($13.50) and disposition at a higher price ($72.50) suggests a potentially profitable execution within the plan's parameters.

Negatives

• The disposition of 300 shares at a significantly higher price ($72.50) compared to the acquisition price ($13.50) could be interpreted as a sale of stock by a company insider, although it is part of a pre-planned strategy.

Risks

• While executed under a 10b5-1 plan, any significant stock sales by key executives can sometimes be perceived negatively by the market, potentially impacting investor sentiment.
• The underlying stock options vest over 48 months, subject to continued service, indicating a potential risk of forfeiture if employment conditions are not met.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance. It solely details insider stock transactions executed under a pre-established trading plan.

Management Comments

• The transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
• The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans by executives is a common practice in the biotechnology and pharmaceutical sectors to manage personal stock portfolios while adhering to insider trading regulations. This filing indicates standard operational procedures for Disc Medicine's Chief Operating Officer.

Stakeholder Impact

• Shareholders: The transactions are executed under a pre-planned strategy, minimizing direct impact on share price due to insider trading concerns. However, any insider selling can still influence market perception.
• Employees: The vesting schedule for stock options is tied to continued employment, aligning executive incentives with company performance.
• Management: Demonstrates adherence to regulatory requirements for insider trading through the use of a 10b5-1 plan.

Next Steps

• Continued vesting of stock options subject to continued service.
• Potential future transactions under the Rule 10b5-1 plan, if applicable.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Disc Medicine, Jonathan Yen-Wen Yu, Stock Options, Beneficial Ownership, Common Stock, SEC Filing